Brief: Blueprint Medicines Submits Supplemental New Drug Application To FDA For Ayvakit (Avapritinib) For Treatment Of Indolent Systemic Mastocytosis
22/11/2022 22:51
Nov 22 (Reuters) - Blueprint Medicines Corp BPMC.O :
* BLUEPRINT MEDICINES SUBMITS SUPPLEMENTAL NEW DRUG
APPLICATION TO
FDA FOR AYVAKIT® (AVAPRITINIB) FOR THE TREATMENT OF INDOLENT
SYSTEMIC MASTOCYTOSIS
Source text for Eikon: ID:nPn1Y9wc4a
Further company coverage: BPMC.O
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G